ProKidney股价飙升,FDA确认加速批准途径

英为财情
Jul 15, 2025

Investing.com -- 在宣布美国食品药品监督管理局(FDA)已确认其慢性肾病疗法rilparencel的加速批准途径后,ProKidney Corp (NASDAQ:PROK)股价最高跳涨12%。 这家处于临床后期的细胞治疗公司透露,FDA同意其正在进行的PROACT 1三期临床试验中的估计肾小球滤过率(eGFR)斜率可作为加速批准途径下生物制品许可申请提交的替代终点。FDA指出,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10